Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience

Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience

Abstract Background This retrospective study evaluates patient-reported outcomes in patients with multiple sclerosis (MS) spasticity who were treated with a cannabinoid oromucosal spray (Sativex®, USAN name: nabiximols) after not sufficiently responding to previous anti-spasticity medications. Metho...

Full description

Bibliographic Details
Main Authors: Marie D’hooghe, Barbara Willekens, Valerie Delvaux, Miguel D’haeseleer, Daniel Guillaume, Guy Laureys, Guy Nagels, Patrick Vanderdonckt, Vincent Van Pesch, Veronica Popescu
Format: Article
Language:English
Published: BMC 2021-06-01
Series:BMC Neurology
Subjects:
Multiple sclerosis spasticity
Observational study
Cannabinoid oromucosal spray
Treatment effect
Treatment satisfaction
Online Access:https://doi.org/10.1186/s12883-021-02246-0

Internet

https://doi.org/10.1186/s12883-021-02246-0

Similar Items